H.R. 9321 · 117th Congress · House

Independent Drug Value Assessment Act

Active· Referred to the Subcommittee on Health.
Introduced
Nov 16, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Independent Drug Value Assessment Act

This bill requires the Office of the Assistant Secretary for Planning and Evaluation to contract with outside entities to conduct independent value assessments of approved drugs (i.e., economic analysis of the benefits to patients and the health care system).

Action Timeline

4
  1. NOV 17, 2022Committee

    Referred to the Subcommittee on Health.

  2. NOV 16, 2022IntroReferral

    Introduced in House

  3. NOV 16, 2022IntroReferral

    Introduced in House

  4. NOV 16, 2022IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

2

Health Subcommittee

hsif14

Referred: Nov 17, 2022

Active

Energy and Commerce Committee

hsif00

Referred: Nov 16, 2022

Active